Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.2K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.2K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

485
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
485
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

177
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
177
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

229
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
229
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

207
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
207
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outbreak of Legionnaires' Disease Associated with Cooling Tower Systems in Central Harlem.

NEJM evidence·2026
Same author

Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program.

The Milbank quarterly·2026
Same author

Growth of dual-eligible special needs plans following permanent authorization.

The American journal of managed care·2026
Same author

Association between 340B contract pharmacy growth and payer-specific drug coverage.

The American journal of managed care·2026
Same author

Market concentration in the ACA individual marketplaces.

Health affairs scholar·2025
Same author

Transfer and Survival of ST-Elevation Myocardial Infarction Medicare Patients.

Cardiology research·2025

Related Experiment Video

Updated: Jan 13, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

10.2K

When Safety-Net Programs Compete: Medicaid, 340B, And The Battle Over Drug Discounts.

Sayeh Nikpay1, Mikayla Reinke2, Elizabeth Watts3

  • 1Sayeh Nikpay (snikpay@umn.edu), University of Minnesota, Minneapolis, Minnesota.

Health Affairs (Project Hope)
|January 6, 2026
PubMed
Summary

The Medicaid Drug Rebate Program and the 340B Drug Pricing Program, while separate, interact to increase Medicaid drug costs. Policy strategies can mitigate this interaction, balancing state savings with 340B organization revenue.

More Related Videos

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

31.1K
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

11.1K

Related Experiment Videos

Last Updated: Jan 13, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

10.2K
A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

31.1K
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

11.1K

Area of Science:

  • Health Policy
  • Pharmaceutical Economics
  • Public Health

Background:

  • The Medicaid Drug Rebate Program (MDRP) subsidizes low-income patients.
  • The 340B Drug Pricing Program (340B) subsidizes safety-net providers.
  • These programs are typically viewed as distinct initiatives for drug affordability.

Purpose of the Study:

  • To examine the interaction between MDRP and 340B.
  • To identify policy strategies to mitigate unintended cost increases for Medicaid.
  • To summarize the adoption of these strategies by states in 2024.

Main Methods:

  • Policy analysis of MDRP and 340B interactions.
  • Review of state-level policy implementations as of 2024.
  • Examination of cost implications for Medicaid and 340B organizations.

Main Results:

  • The interaction between MDRP and 340B can lead to increased costs for the Medicaid program.
  • Two policy strategies have been identified to mitigate these cost increases.
  • States are increasingly adopting these strategies, with varying approaches observed in 2024.

Conclusions:

  • Policymakers must consider the trade-offs between preserving Medicaid savings and potential revenue loss for 340B organizations.
  • Strategic policy adjustments are needed to optimize the effectiveness of both programs.
  • Further research is recommended on the long-term financial impact of these interactions and mitigation strategies.